- Home
- FEDU vs CGTX Comparison
FEDU vs CGTX Comparison
Compare FEDU & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- CGTX
- Stock Information
- Founded
- FEDU 2007
- CGTX 2007
- Country
- FEDU China
- CGTX United States
- Employees
- FEDU N/A
- CGTX N/A
- Industry
- FEDU
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- CGTX Health Care
- Exchange
- FEDU NYSE
- CGTX Nasdaq
- Market Cap
- FEDU 20.0M
- CGTX 23.1M
- IPO Year
- FEDU 2017
- CGTX 2021
- Fundamental
- Price
- FEDU $7.72
- CGTX $0.40
- Analyst Decision
- FEDU
- CGTX Strong Buy
- Analyst Count
- FEDU 0
- CGTX 5
- Target Price
- FEDU N/A
- CGTX $7.13
- AVG Volume (30 Days)
- FEDU 16.5K
- CGTX 566.8K
- Earning Date
- FEDU 12-20-2024
- CGTX 05-06-2025
- Dividend Yield
- FEDU 29.53%
- CGTX N/A
- EPS Growth
- FEDU N/A
- CGTX N/A
- EPS
- FEDU 0.12
- CGTX N/A
- Revenue
- FEDU $27,971,139.00
- CGTX N/A
- Revenue This Year
- FEDU N/A
- CGTX N/A
- Revenue Next Year
- FEDU N/A
- CGTX N/A
- P/E Ratio
- FEDU $64.77
- CGTX N/A
- Revenue Growth
- FEDU 141.14
- CGTX N/A
- 52 Week Low
- FEDU $3.69
- CGTX $0.31
- 52 Week High
- FEDU $22.70
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- FEDU 47.63
- CGTX 49.16
- Support Level
- FEDU $7.58
- CGTX $0.35
- Resistance Level
- FEDU $7.89
- CGTX $0.45
- Average True Range (ATR)
- FEDU 0.93
- CGTX 0.04
- MACD
- FEDU 0.17
- CGTX 0.01
- Stochastic Oscillator
- FEDU 91.38
- CGTX 65.03
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.